<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584738</url>
  </required_header>
  <id_info>
    <org_study_id>HGNAE-03</org_study_id>
    <nct_id>NCT02584738</nct_id>
  </id_info>
  <brief_title>Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation</brief_title>
  <official_title>Efficacy of Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation. A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Naval de Alta Especialidad - Escuela Medico Naval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General Naval de Alta Especialidad - Escuela Medico Naval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effectiveness of nebulized magnesium sulfate
      in patient with moderate to severe asthma exacerbation in pediatric emergency
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The inclusion period of the patients in this research will be on September 2015 to November
      2015. Patients are going to be selected by the medical staff on duty in the emergency
      paediatric service, according to the criteria previously established inclusion and exclusion.
      Immediately a baseline degree of respiratory distress using PRAM scale and heart rate,
      respiratory rate, blood pressure and oxygen saturation. While informed consent in which the
      objective and characteristics of the study will be obtained will be explained.

      Patients will be randomly assigned one of the two treatments in the Research: standard
      treatment for moderate to severe asthma attack, according to GINA or standard treatment plus
      nebulised magnesium sulphate, according to the table of random allocation of treatment.

      Evaluations were performed after administration of each spray, that is, at 20, 40, 60, 120,
      180 and 240 minutes after beginning treatment. The parameters' to evaluate are going to be
      heart rate, respiratory rate, oxygen saturation, blood pressure and assessment of severity of
      acute asthma with PRAM scale.

      The application of nebulized drugs are made in the emergency department of pediatrics by
      inhalation therapy staff who are also responsible for the preparation of medicines. It is
      clear that this staff not participate in the evaluation of patients, which will be performed
      by the research staff or by medical staff on duty in the pediatric emergency department.

      Patients and evaluating physician will not pick out between the two solutions for
      nebulization not only colour but also smell or other special feature, because the solutions
      were arranged in two identical syringes. Administered alone at the end of the study treatment
      is known.

      Later the entry or exit of the patient decide, who can be egress to show clinical improvement
      with decreased severity index PRAM, patients will be graduates of an outpatient treatment
      according to international guidelines on the management of acute asthma. All initial and
      outcome data will be recorded in a format of data collection All decisions will be made by
      patients pediatricians emergency department which will follow patients throughout the study
      and will have the power to release the study patients to use other interventions that they
      consider clinically necessary
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Preschool Respiratory Assessment Measure (PRAM)</measure>
    <time_frame>20, 40, 60, 120, 180 and 240 minutes after beginning treatment</time_frame>
    <description>Scalene muscle contraction, Suprasternal retractions, Wheezing, Air entry and O2 saturation.
The score will be considering from the addition per each primary measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Scalene muscle contraction</measure>
    <time_frame>20, 40, 60, 120, 180 and 240 minutes after beginning treatment</time_frame>
    <description>Absent (0) or Present (2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Suprasternal retractions</measure>
    <time_frame>20, 40, 60, 120, 180 and 240 minutes after beginning treatment</time_frame>
    <description>Absent (0) or Present (2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Wheezing</measure>
    <time_frame>20, 40, 60, 120, 180 and 240 minutes after beginning treatment</time_frame>
    <description>Normal (0), Decreased at bases (1), Widespread decrease (2), or Absent/minimal (3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Air entry</measure>
    <time_frame>20, 40, 60, 120, 180 and 240 minutes after beginning treatment</time_frame>
    <description>Absent (0), Expiratory only (1), Inspiratory and expiratory (2) or Audible without (3) stethoscope/silent chest with minimal air entry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline O2 saturation</measure>
    <time_frame>20, 40, 60, 120, 180 and 240 minutes after beginning treatment</time_frame>
    <description>≥95% (0), 92%-94% (1) or &lt;92% (2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalization</measure>
    <time_frame>4 hour</time_frame>
    <description>Reduction the rate of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Heart rate</measure>
    <time_frame>20, 40, 60, 120, 180 and 240 minutes after beginning treatment</time_frame>
    <description>Beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Respiratory rate</measure>
    <time_frame>20, 40, 60, 120, 180 and 240 minutes after beginning treatment</time_frame>
    <description>Breaths per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Blood pressure</measure>
    <time_frame>60 minutes after beginning treatment</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Nebulized Magnesium Sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4.
Intravenous methylprednisolone or oral prednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebulized isotonic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nebulized salbutamol and ipratropium bromide with 2.5 ml of isotonic saline. Intravenous methylprednisolone or oral prednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Magnesium Sulfate</intervention_name>
    <description>Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.
will be continued with nebulized standard treatment every hour for 4 hours.</description>
    <arm_group_label>Nebulized Magnesium Sulfate</arm_group_label>
    <other_name>MgSO4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized isotonic saline</intervention_name>
    <description>Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.
will be continued with nebulized standard treatment every hour for 4 hours.</description>
    <arm_group_label>Nebulized isotonic saline</arm_group_label>
    <other_name>Standard treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Salbutamol</intervention_name>
    <description>Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)</description>
    <arm_group_label>Nebulized Magnesium Sulfate</arm_group_label>
    <arm_group_label>Nebulized isotonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium bromide</intervention_name>
    <description>Nebulized ipratropium bromide 250 mcg</description>
    <arm_group_label>Nebulized Magnesium Sulfate</arm_group_label>
    <arm_group_label>Nebulized isotonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone or Prednisolone</intervention_name>
    <description>Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment</description>
    <arm_group_label>Nebulized Magnesium Sulfate</arm_group_label>
    <arm_group_label>Nebulized isotonic saline</arm_group_label>
    <other_name>Corticosteroid therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of moderate or severe asthma exacerbations

          -  2 to 15 years old.

          -  Served in the pediatric emergency department of naval high specialty General Hospital
             from September to December 2015.

          -  Signing the consent by the parents.

        Exclusion Criteria:

          -  Coexistence of lung disease.

          -  Severe kidney disease.

          -  Severe liver disease.

          -  Pregnancy.

          -  Known previous reaction to magnesium.

          -  Parents who have not signed the agreement.

          -  Patients without a clinical history of asthma.

          -  Clinical diagnosis of mild asthma attack.

          -  Previously included in the study.

          -  Presence of comorbidities that endanger the patient's life.

          -  The patient has clinical or gasometric criteria for advanced airway management.

          -  Life-threatening symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús Abisai Uicab Saucedo, Pediatrician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Secretaria de Marina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesús Abisai Uicab Saucedo, Pediatrician</last_name>
    <phone>(52)5550371200</phone>
    <phone_ext>5423</phone_ext>
    <email>abisaipec@msn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General Naval de Alta Especialidad</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>04480</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Abisai Uicab Saucedo, Pediatrician</last_name>
      <phone>(52)5550371200</phone>
      <phone_ext>5423</phone_ext>
      <email>abisaipec@msn.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.ginasthma.org</url>
    <description>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (Updated 2015).</description>
  </link>
  <link>
    <url>http://www.brit-thoracic.org.uk/clinical-information/asthma/asthma-guidelines.aspx</url>
    <description>British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guidelines on the management of asthma—a national clinical guideline British Thoracic Society (October 2014).</description>
  </link>
  <reference>
    <citation>Birken CS, Parkin PC, Macarthur C. Asthma severity scores for preschoolers displayed weaknesses in reliability, validity, and responsiveness. J Clin Epidemiol. 2004 Nov;57(11):1177-81. Review.</citation>
    <PMID>15567635</PMID>
  </reference>
  <reference>
    <citation>Gorelick MH, Stevens MW, Schultz TR, Scribano PV. Performance of a novel clinical score, the Pediatric Asthma Severity Score (PASS), in the evaluation of acute asthma. Acad Emerg Med. 2004 Jan;11(1):10-8.</citation>
    <PMID>14709423</PMID>
  </reference>
  <reference>
    <citation>Rodrigo GJ, Plaza Moral V, Forns SB, Castro-Rodríguez JA, de Diego Damiá A, Cortés SL, Moreno CM, Nannini LJ, Neffen H, Salas J; SEPAR; ALAT. [ALERTA 2 guidelines. Latin America and Spain: recommendations for the prevention and treatment of asmatic exacerbations. Spanish Pulmonology and Thoracic Surgery Society (SEPAR). Asthma Department of the Latinamerican Thoracic Association (ALAT)]. Arch Bronconeumol. 2010 Oct;46 Suppl 7:2-20. doi: 10.1016/S0300-2896(10)70041-7. Spanish.</citation>
    <PMID>21320808</PMID>
  </reference>
  <reference>
    <citation>Gourgoulianis KI, Chatziparasidis G, Chatziefthimiou A, Molyvdas PA. Magnesium as a relaxing factor of airway smooth muscles. J Aerosol Med. 2001 Fall;14(3):301-7.</citation>
    <PMID>11693841</PMID>
  </reference>
  <reference>
    <citation>Dominguez LJ, Barbagallo M, Di Lorenzo G, Drago A, Scola S, Morici G, Caruso C. Bronchial reactivity and intracellular magnesium: a possible mechanism for the bronchodilating effects of magnesium in asthma. Clin Sci (Lond). 1998 Aug;95(2):137-42.</citation>
    <PMID>9680494</PMID>
  </reference>
  <reference>
    <citation>Cairns CB, Kraft M. Magnesium attenuates the neutrophil respiratory burst in adult asthmatic patients. Acad Emerg Med. 1996 Dec;3(12):1093-7.</citation>
    <PMID>8959161</PMID>
  </reference>
  <reference>
    <citation>Mohammed S, Goodacre S. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. Emerg Med J. 2007 Dec;24(12):823-30. Review.</citation>
    <PMID>18029512</PMID>
  </reference>
  <reference>
    <citation>Shan Z, Rong Y, Yang W, Wang D, Yao P, Xie J, Liu L. Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis. Respir Med. 2013 Mar;107(3):321-30. doi: 10.1016/j.rmed.2012.12.001. Epub 2013 Jan 3. Review.</citation>
    <PMID>23290189</PMID>
  </reference>
  <reference>
    <citation>Powell C, Dwan K, Milan SJ, Beasley R, Hughes R, Knopp-Sihota JA, Rowe BH. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev. 2012 Dec 12;12:CD003898. doi: 10.1002/14651858.CD003898.pub5. Review. Update in: Cochrane Database Syst Rev. 2017 Nov 28;11:CD003898.</citation>
    <PMID>23235599</PMID>
  </reference>
  <reference>
    <citation>Goodacre S, Cohen J, Bradburn M, Gray A, Benger J, Coats T; 3Mg Research Team. Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial. Lancet Respir Med. 2013 Jun;1(4):293-300. doi: 10.1016/S2213-2600(13)70070-5. Epub 2013 May 17.</citation>
    <PMID>24429154</PMID>
  </reference>
  <reference>
    <citation>Powell CV, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, Hood K, Williamson PR; MAGNETIC study group. MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children. Health Technol Assess. 2013 Oct;17(45):v-vi, 1-216. doi: 10.3310/hta17450.</citation>
    <PMID>24144222</PMID>
  </reference>
  <reference>
    <citation>Alansari K, Ahmed W, Davidson BL, Alamri M, Zakaria I, Alrifaai M. Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial. Pediatr Pulmonol. 2015 Dec;50(12):1191-9. doi: 10.1002/ppul.23158. Epub 2015 Feb 4.</citation>
    <PMID>25652104</PMID>
  </reference>
  <reference>
    <citation>Rowe BH. Intravenous and inhaled MgSO4 for acute asthma. Lancet Respir Med. 2013 Jun;1(4):276-7. doi: 10.1016/S2213-2600(13)70097-3. Epub 2013 May 17. Review.</citation>
    <PMID>24429139</PMID>
  </reference>
  <reference>
    <citation>Petrou S, Boland A, Khan K, Powell C, Kolamunnage-Dona R, Lowe J, Doull I, Hood K, Williamson P. Economic evaluation of nebulized magnesium sulphate in acute severe asthma in children. Int J Technol Assess Health Care. 2014 Oct;30(4):354-60. doi: 10.1017/S0266462314000440. Epub 2014 Nov 14.</citation>
    <PMID>25394502</PMID>
  </reference>
  <reference>
    <citation>Wang H, Xiong Y, Gong C, Yin L, Yan L, Yuan X, Liu S, Shi T, Dai J. Effect of inhaled magnesium sulfate on bronchial hyperresponsiveness. Indian J Pediatr. 2015 Apr;82(4):321-7. doi: 10.1007/s12098-014-1476-6. Epub 2014 Jun 12.</citation>
    <PMID>24916134</PMID>
  </reference>
  <results_reference>
    <citation>Smith SR, Baty JD, Hodge D 3rd. Validation of the pulmonary score: an asthma severity score for children. Acad Emerg Med. 2002 Feb;9(2):99-104.</citation>
    <PMID>11825832</PMID>
  </results_reference>
  <results_reference>
    <citation>Chalut DS, Ducharme FM, Davis GM. The Preschool Respiratory Assessment Measure (PRAM): a responsive index of acute asthma severity. J Pediatr. 2000 Dec;137(6):762-8.</citation>
    <PMID>11113831</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Exacerbation</keyword>
  <keyword>Nebulization</keyword>
  <keyword>Magnesium</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

